
|Articles|October 8, 2014
Collaboration Will Help Match the Right Patient With the Right Trial
The collaboration between med fusion and GenomOncology promises improved outcomes in personalized cancer trials.
Advertisement
med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical WorkbenchTM, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
Press release:
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
5




